{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/biohaven-advances-a-new-class-of-precision-immunology-therapies-first-mode-extracellular-protein-degrader-bhv-1300-begins-phase-3-pivotal-trial-in-graves-disease-302812720.html", "message": "News view counter 820278 successfully enlarged"}